Literature DB >> 11504989

'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo.

J Weber1, A Nunn, T O'Connor, D Jeffries, V Kitchen, S McCormack, J Stott, N Almond, A Stone, J Darbyshire.   

Abstract

BACKGROUND: Vaginal agents which are antiviral and/or inhibit the entry of HIV into the cell could prevent heterosexual transmission of HIV, and protect women who cannot negotiate condom use.
METHODS: Four agents have been investigated for activity in vitro and in vivo against SHIV(89.6PD): two anionic polymers, dextrin-2-sulphate (D2S) and PRO 2000 (P2K), and two virucidal agents; a non-ionic detergent, nonoxynol-9 (N9) and a cyclic peptide ionophore, gramicidin-D (GD). All four agents were investigated in rhesus macaques, using an intra-vaginal challenge of two inoculations of 1 x 104 50% tissue culture infectious doses (TCID)50 of SHIV(89.6PD).
RESULTS: D2S, P2K, GD and N9 all inhibited SHIV(89.6PD) in vitro. In vivo, three out of four control macaques were infected as judged by viral culture, seroconversion, DNA and RNA PCR; infection was confirmed in four out of eight macaques pre-treated with P2K, two out of four pre-treated with D2S, one out of four pre-treated with N9, two out of four pre-treated with GD and four out of four pre-treated with D2S + GD, a combination additive in vitro.
INTERPRETATION: D2S and PRO-2000, novel inhibitors of HIV entry, showed evidence of protection in vivo, comparable to that seen with the virucide, N9. These data, together with the results of phase I and phase II studies in healthy women which have shown minimal toxicity, support plans for a phase III efficacy trial of chemically simple inhibitors of HIV entry with low toxicity, for the prevention of HIV infection in women.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11504989     DOI: 10.1097/00002030-200108170-00014

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  27 in total

1.  In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides.

Authors:  Youssef Gali; Olivier Delezay; Joachim Brouwers; Noura Addad; Patrick Augustijns; Thomas Bourlet; Hind Hamzeh-Cognasse; Kevin K Ariën; Bruno Pozzetto; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Formulation, pharmacokinetics and pharmacodynamics of topical microbicides.

Authors:  Jessica L Adams; Angela D M Kashuba
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-02-04       Impact factor: 5.237

Review 3.  Emerging drug targets for antiretroviral therapy.

Authors:  Jacqueline D Reeves; Andrew J Piefer
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  Phosphorothioate 2' deoxyribose oligomers as microbicides that inhibit human immunodeficiency virus type 1 (HIV-1) infection and block Toll-like receptor 7 (TLR7) and TLR9 triggering by HIV-1.

Authors:  Joseph A Fraietta; Yvonne M Mueller; Duc H Do; Veronica M Holmes; Mary K Howett; Mark G Lewis; Alina C Boesteanu; Sefik S Alkan; Peter D Katsikis
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 5.  Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention.

Authors:  Joseph Romano; Angela Kashuba; Stephen Becker; James Cummins; Jim Turpin; Fulvia Veronese
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-22       Impact factor: 2.205

Review 6.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

Review 7.  Overview of microbicides for the prevention of human immunodeficiency virus.

Authors:  Salim S Abdool Karim; Cheryl Baxter
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2012-03-02       Impact factor: 5.237

8.  PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

Authors:  Sheena McCormack; Gita Ramjee; Anatoli Kamali; Helen Rees; Angela M Crook; Mitzy Gafos; Ute Jentsch; Robert Pool; Maureen Chisembele; Saidi Kapiga; Richard Mutemwa; Andrew Vallely; Thesla Palanee; Yuki Sookrajh; Charles J Lacey; Janet Darbyshire; Heiner Grosskurth; Albert Profy; Andrew Nunn; Richard Hayes; Jonathan Weber
Journal:  Lancet       Date:  2010-09-17       Impact factor: 79.321

9.  Candidate polyanionic microbicides inhibit human T-cell lymphotropic virus type 1 receptor interactions, cell-free infection, and cell-cell spread.

Authors:  Daniela Romer; David W Brighty; Cynthia L Robson; Quentin J Sattentau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-01       Impact factor: 5.191

Review 10.  Dermaseptins and magainins: antimicrobial peptides from frogs' skin-new sources for a promising spermicides microbicides-a mini review.

Authors:  Amira Zairi; Frédéric Tangy; Khaireddine Bouassida; Khaled Hani
Journal:  J Biomed Biotechnol       Date:  2009-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.